Origin Materials

CapFormer Will Transform $65B PET Caps Market Amid Risks

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

20 Apr 25

Updated

01 May 25

Views

124

01 May

US$1.53

AnalystConsensusTarget's Fair Value

US$0.46

232.6% overvalued

-89.4%

7.0%

-89.4%

7.0%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$0.46232.6% overvalued

AnalystConsensusTarget Fair Value

Shared on 01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

1 view

Shared on 24 Apr 25

Fair value Decreased 8.00%

AnalystConsensusTarget has decreased future PE multiple from 6.7x to 6.0x and decreased shares outstanding growth rate from 0.1% to -0.0%.

0 views

Valuator

Company Info

Notes

AnalystConsensusTarget Fair Value

US$0.46

232.6% overvalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

0.00%

Historical revenue growth rate

49.04%

Chemicals revenue growth rate

0.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.13%

Calculation

US$12.98m

Earnings '28

6.12x

PE Ratio '28

US$79.39m

Market Cap '28

US$79.39m

Market Cap '28

141.32m

No. shares '28

US$0.56

Share Price '28

US$0.56 Share Price '28

Discounted to 2025 @ 6.89% p.a.

US$0.46

Fair Value '25